A.P. Møller - Mærsk A/S
Transactions in connection with share buy-back program
Transactions in connection with share buy-back program
Announcement
 
 
A.P. Møller - Mærsk A/S – Transactions in connection with share buy-back program
 
 
On 5 February 2025, A.P. Møller - Mærsk A/S (the “Company”) announced a share buy-back program of up to DKK 14.4bn (around USD 2bn) to be executed over a period of 12 months. The second phase of the share buy-back program will run from 11 August 2025 up to 4 February 2026. The shares to be acquired will be limited to a total market value of DKK 7.2 billion (around USD 1.1 billion).           
            
The share buy-back program will be executed under EU Commission Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”).                             
The following transactions have been made under the program in the period 27 to 31 October, 2025:
| Number of A shares | Average purchase price A shares, DKK |  Transaction   value, A shares, DKK  | |
| Accumulated, last announcement | 128,220 | 1,565,319,040 | |
| 27 October 2025 | 600 | 13,265.8833 | 7,959,530 | 
| 28 October 2025 | 625 | 13,458.3840 | 8,411,490 | 
| 29 October 2025 | 625 | 13,863.1040 | 8,664,440 | 
| 30 October 2025 | 600 | 13,634.9561 | 8,180,974 | 
| 31 October 2025 | 600 | 13,392.9333 | 8,035,760 | 
| Total 27-31 October 2025 | 3,050 | 41,252,194 | |
| Accumulated in the second phase of the program | 40,801 | 538,506,144 | |
| Accumulated under the program | 131,270 | 1,606,571,234 | |
| Number of B shares | Average purchase price B shares, DKK |  Transaction   value, B shares, DKK  | |
| Accumulated, last announcement (market and the Foundation) | 726,374 | 8,964,358,189 | |
| 27 October 2025 | 3,006 | 13,321.2375 | 40,043,640 | 
| 28 October 2025 | 3,132 | 13,518.3541 | 42,339,485 | 
| 29 October 2025 | 3,132 | 13,918.4866 | 43,592,700 | 
| 30 October 2025 | 3,006 | 13,610.1281 | 40,912,045 | 
| 31 October 2025 | 3,006 | 13,418.2302 | 40,335,200 | 
| Total 27-31 October 2025 | 15,282 | 207,223,070 | |
| Bought from the Foundation* | 1,999 | 13,560.0279 | 27,106,496 | 
| Accumulated in the second phase of the program (market and the Foundation) | 231,190 | 3,066,755,101 | |
| Accumulated under the program (market and the Foundation) | 743,655 | 9,198,687,755 | 
*) According to a separate agreement, A.P. Møller og Hustru Chastine Mc-Kinney Møllers Familiefond (the Foundation) participates on a pro rata basis to the shares purchased in the share buy-back program.
 With the transactions stated above, the Company owns a total of 131,270 A shares and 843,456 B shares as treasury shares, corresponding to 6.16% of the share capital.
Details of each transaction are included as appendix.
Copenhagen, 3 November, 2025
Contact persons:
Head of Investor Relations, Stefan Gruber, tel. +45 3363 3484
Head of Media Relations, Jesper Lov, tel. +45 6114 1521
 
 
Page 1 of 1
 
Attachments
- Announcement - Transactions in connection with share buy-back program - week 44 2025
 - Daily transactions in connection with share buy-back program - week 44 2025
 
 
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Sveriges Riksbank4.11.2025 09:30:00 CET | Press release
CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES
Virtune AB (Publ)4.11.2025 09:18:43 CET | Press release
Virtune AB (Publ) ("Virtune") has completed the monthly rebalancing for October 2025 of its Virtune Crypto Top 10 Index ETP - the first crypto index ETP in the Nordics
Quantexa4.11.2025 09:00:00 CET | Press release
Quantexa Makes Its Decision Intelligence Platform ‘Agent Ready’ to Solve the Hardest Problems in AI: Data Fragmentation & Context
Aalborg Boldspilklub A/S4.11.2025 08:50:49 CET | Pressemeddelelse
Bestyrelsen i AaB A/S indleder proces for kapitaludvidelse primo 2026
Karolinska Development AB (publ)4.11.2025 08:45:00 CET | Press release
Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom